National day in U.A.E Essay Example | Topics and Well Written Essays - 250 words

National day in U.A.E - Essay Example What is its significance for citizens? Facts about the UAE The UAE is a Middle Eastern federation of seven states situated in the southeast of the Arabian peninsula in the southwest Asia on the Arabian Gulf, bordering, Oman and Saudi Arabia, from tribally organized peninsula. The seven states of Emirates are Abu Dhabi, Dubai, Sharjah, Ajman, Umm – AlQwain, Ras AlKhaimah and Fujairah. Immense wealth has been invested in numerous development projects, capital improvements, social services throughout the UAE. It is one of the most developed federations in the world. Over 200 nationalities and cultures are represented here. Therefore professional Arabic translation and interpretation services play a major role. The UAE’s History Near the end of the nineteenth century, the UK and the Trucial sheikdoms established close bonds in 1892 treaty. One of these bonds is that British promised to protect the Trucial Coast from all aggression by sea and to help in case of land attack. After the First World War, Japan invented the cultured pearl. Their invention destroyed our â€Å"Natural Pearlsâ€Å" that means they became worthless. This affected our economy and business. In the early 1960s, oil was discovered in Abu Dhabi. As a result, Sheikh Zayed undertook a massive construction program, building schools, housing, hospitals and roads.

Albinism Essay Example for Free

Albinism Essay Albinism Background Information Albinism is a genetic disorder which affects the amount of melanin produced, in a person’s skin, hair, or eyes. Oculocutaneous albinism, Ocular albinism, and Hermansky-Pudlak syndrome are other names for this genetic disorder. The disorder affects mostly men, because it is a recessive gene. Females are usually carriers. Albinism does not affect any specific ethnic or religious group. Symptoms/ Effects This Genetic Disorder affects the eyes, skin, or hair’s pigmentation. If an organism has albinism, it has little or no color in a specific part of its body. Albinistic skin burns easily. People with this disorder have to take special precautions to avoid sunburns and diseases such as skin cancer. Most types of Albinism also affect the eyes. Symptoms affecting the eyes include Crossed eyes, Light sensitivity, Rapid eye movements, Vision problems, and functional blindness. Albinistic people may have to limit their outdoor activities to avoid too much exposure to the sun. This disorder itself is not life threatening. However albinism affects many animals’ camouflage, and makes them easy prey. A human’s life span can be shortened by lung disease or bleeding problems from a form of Albinism, Hermansky-Pudlak Syndrome. Testing/ Diagnostics This disorder can be detected simply by looking for pale or unnatural colored eyes, hair, or skin. To make sure, scientists use genetic tests to affirm that a person has albinism. Ophthalmologists also conduct electroretinograms to detect any optical problems. Causes Albinism is a recessive gene that can only be inherited. It is not sex-linked. Treatments Albinism cannot be cured, but it a person with albinism can wear colored contacts or sunglasses to comfort and protect their eyes. They can wear sun block and stay indoors to protect their skin. Name: Vivian Ray (Vivia)? Age: 17? Gender: F? Appearance: There, you see her first thing you notice when you see Vivia, is her grace. From her delicate structure to her fluid motions, she is elegant and nimble. Vivia has dark black/brown hair pulled into a messy bun with an ornate pen sticking out of it. She has overgrown bangs, that fall into her face. She has an odd way of talking, she looks at you straight in the eyes with her bright grey irises, while speaking with long embellished sentences in a melodic voice. Vivia does not appear to be intimidating or weak. But at the same time, both. She holds herself tall and her eyes seem be a portal to her her inner depths.? Abilities/Talents: Vivia once ice-skated and did ballet. She is moderately athletic. Vivia’s main talent is writing. She often walks around in the park trying to find the perfect word to decribe the leaves slowly falling down, or the prints in the snow. She has her own column in the Elwood High newspaper called â€Å"On the Bright Side†? Basic Likes/Dislikes:? Likes: Vivia like things that are well though out, poems, artwork, and anything else. She loves sour things, and is often sucking a lemon head. When asked her favorite color she thinks of her late mother’s grey eyes (the only trait she inherited from her mother) and replies without hesitation, grey. She loves fruit and would pick it over any other dessert, likes listening to instrumental music . She also likes to reread her dog-eared copies of Shakespeare in her free time.? Dislike: The number one thing Vivia dislikes is being wrong. She does not like the uncertainty and indecisiveness she often suffers from. She also does not like people who stereotype and make assumptions about her. She tends to not work as hard if she is forced to do something instead of herself choosing to do something. Vivia also absolutely hates suspense, and has yet to read a full mystery without skipping to the end.? Personality: Vivia, is usually not the loudest person, and often simply listens in the background. However, her writing truly shows who she is, and wants to be. She is often caught dreaming about what would happen if her life were different. She has a temper if you annoy her enough to find it. She can be stubborn, and is very fair.? Background Information: As a senior at Aberle High, Vivia is being pressured into making the big decision as to what career path she should choose. Her father is pushing her toward a doctorate, while she would rather become an author.? Relationships: Vivia’s mother was a journalist and died in a car accident while driving to the scene of er next story. She lives with her father and little brother. She loves her father and wants to make him proud. There, you see her, leaning against a tree

Nursing Processes for Emesis Management

Nursing Processes for Emesis Management Nausea and vomiting are common complications of multiple conditions, procedures, therapies, and events such as motion sickness, pregnancy, anesthesia (general, regional, or local) or radio/chemotherapy. Symptoms can be debilitating for many patients, and in the case of post-operative nausea and vomiting (PONV) physical damage may result, such as rupture of sutures, stitches, and esophageal tissue, and metabolic problems, such as electrolyte imbalances and dehydration (Golembiewski et al, 2005; Gan 2006). In severe cases of PONV, although rare, aspiration of gastric contents may occur, resulting in pulmonary sequelae, such as pneumonia or pneumothorax (Scuderi and Conlay 2003; Bremner and Kumar 1993). Thus effective treatment of PONV, possibly through multimodal antiemetic prophylaxis, is an important are of research (Skledar et al. 2007). This essay will consider two commonly used, well-recognized antiemetic treatments namely cyclizine and prochlorperazine. Both represent very old drug therapies, with cyclizine having been launched as an antiemetic in 1953, and prochlorperazine as an antipsychotic in 1957 (Broccatelli, 2010), its use as an effective antiemetic emerging soon thereafter (Finn et al, 2005). These drugs are commonly used on most wards in my practice setting and therefore it is vital for nursing staff to understand their respective pharmacodynamic (PD) and pharmacokinetic (PK) profiles. Prior to prescribing it is also important that the nurse have relevant knowledge regarding how these drugs work, how their PD and PK properties are altered by disease processes such as kidney/liver failure and whether there are any relevant contraindications or precautions. Additionally, the potential for drug-drug interactions and the dose appropriate for the patients age and weight should be ascertained if beneficial pati ent orientated outcomes are to be achieved. These issues will be comprehensively discussed within this essay. Pharmacology of emesis There are a plethora of drugs on the market to treat emesis, however, deciding upon an appropriate and effective treatment for patients requires the cause of the underlying nausea and vomiting to be ascertained. This is because the symptoms can manifest as a result of a number of underlying pharmacological processes, as will now be described. Vomiting is a complex reflex action controlled by the vomiting centre (VC) in the medulla region of the brain, an important part of which is the chemotrigger zone (CTZ); stimulation of this in turn leads to VC stimulation which ultimately leads to vomiting (Goodman Gilman, 1996). Neurotransmitter mediated stimulation of the VC can arise from both peripheral and central impulses (Shanbhag, 2008). Thus gastrointestinal irritation, motion sickness and vestibular neuritis all manifest in nausea and vomiting as a result of neurotransmitter release. The three main neurotransmitters involved in the control of vomiting are acetylcholine (ACh; via muscarinic-receptors), dopamine (via dopaminergic receptors), histamine (via H-1 receptors), and serotonin (via 5-HT3 receptors) (Shanbhag, 2008). Inhibition or antagonism of these receptors achieves emetic control. The VC has neurons which are rich in muscarinic cholinergic and histamine containing synapses and is directly stimulated by the vestibular input (e.g. through motion sickness), whilst dopamine and serotonin release are involved in the visceral stimuli pathway (e.g. through chemotherapy treatment) and also in the CTZ stimulation pathway as shown in Figure 1. Thus drug classifications of anti-emetics arise on the basis of which of the three pathways that they target (Flake et al., 2004). Selective serotonin receptor antagonists and antidopaminergics target the visceral stimuli and the CTZ, whilst the antihistamines and anticholinergics target the vestibular input pathway (Hornby , 2001; Flake et al., 2004). Etiology of Nausea and Vomiting Cyclizines anti-emetic effects are not fully understood but it is thought that it works by blocking the transmission of information from the labyrinthine apparatus in the inner ear (i.e. the vestibular pathway) to the VC (Goodman and Gillman, 1996). Cyclizine may also target the CTZ and it thought to exhibit some ACh muscarinic receptor blockade which probably contribute to the antiemetic potential thus operating at several pathophysiological levels. However, a side effect of ACh blockade is sedation in some individuals along with the potential for certain deliriant and hallucinogenic effects, probably responsible for cyclizines abuse potential (Bailey and Davies, 2008). Cyclizine produces its antiemetic effect within two hours and it lasts approximately four hours (emc, n.d.). The exact mechanism of prochlorperazines antiemetic action is also unclear, but the drug is thought to inhibit apomorphine induced vomiting by blocking dopamine D2 receptors centrally in the CTZ and possibly peripherally through dopaminergic receptors in the intestine (Perwitasari, 2011).   However, it also has some potential to block anticholinergic and alpha-adrenergic receptors, and therefore can also result in sedation along with muscle relaxation, and orthostatic hypotension (Kelly, 2000). Following intramuscular administration prochlorperazine has an onset of action within ten to twenty minutes and a duration of action of three to four hours (globalrph, n.d.). Indications and dosage form Cyclizine is indicated for the control of postoperative and drug-induced vomiting and in motion sickness (BNF, 2012; emc, n.d.). It is given by mouth at a dose of 50mg tablets up to three times a day or parenterally as a 50mg in 1ml solution intramuscular (im) or intravenous (iv) injection again at a frequency of up to 3 times a day (Reynolds, 1993). The recommended dose in children aged 6-12 years is lower: 25 mg up to 3 times daily. For motion sickness, it is recommended that tablets be taken 1-2 hours before departure. Cyclizine can also be given for vertigo and, morning sickness in pregnancy, and to combat  opioid nausea. It is also prescribed for radiation sickness (medsafe, n.d.) and PONV (Cholwill et al., 1999), indeed it is given iv before the induction of general anaesthesia at half the recommended dose, to increase the lower oesophageal sphincter tone thus reducing the hazard of regurgitation and aspiration of gastric contents (medsafe, n.d.). Although prochlorperazine is classified as an antipsychotic, its principal use nowadays is in the treatment of severe nausea and vomiting of various causes including, PONV, vertigo and motion sickness (BNF, 2012). It has several dosage forms: tablet (5mg: one or two tablets 3-4 times daily), syrup (5mg in 5ml: 5-10 ml 3-4 times daily), suppositories (25mg twice daily), dissolvable tablet (buccal tablet 3mg: one or two tablets twice a day in adults and children aged 12 years and over), im injection (12.5mg in 1ml; 5-10mg repeated every 3-4 hours with a maximum daily dose of 40mg) and iv injection (2.5 -10 mg by slow IV injection or infusion  with a maximum daily dose of 40mg). The oral (and buccal) route is the only method of administration recommended for children, and it is not recommended in children younger than  12 years (BNF, 2012). The different dosage form of prochlorperazine provides the nurse with flexibility for example the elderly and children may prefer the syrup or b uccal tablet, or in dysphagia suppositories or intra-muscular injections could be more appropriate. Cyclizine and prochlorperazine are both considered first line treatments for nausea secondary to vertigo and motion sickness (Quigley, 2001) and are first line treatments in many hospitals in PONV (NHS, Salisbury; NHS Plymouth). A review by Matchar, et al. (2003) has suggested that oral prochloperazine may also be used as an adjunct in the treatment of nausea associated with migraine (Matchar et al, n.d.). No randomized controlled trial has been found which formally compares efficacy of cyclizine and prochlorperazine, however, two studies comparing cyclizine with perphenazine in ameliorating drug-induced emesis, have shown the former to have comparable antiemetic efficacy to this related phenothiazine drug (Dundee et al., 1975; Chestnutt and Dundee, 1986). These studies are featured in a Cochrane report (Stevenson, 2006) which investigates drugs for preventing PONV and highlights eight drugs which reduce PONV by a similar amount in this patient group, cyclizine being one. The report concluded, therefore, that the most important question to answer when treating emesis is What are the types and risks of side effects experienced by patients exposed to these antiemetics? Thus safe and effective prescribing requires the nurse to identify patient variables or comorbidities relevant to the drugs side effects, for example heart failure patients should not be prescribed cyclizine and individuals susceptible to visual disturbances should avoid prochlorperazine as per the drugs contraindications. It is noteworthy that both drugs may be prescribed in the later stages of pregnancy if considered appropriate by a doctor (Schaefer, 2007; CKS, n.d.).  [1]   The choice of antiemetic would depend upon the precise cause of the nausea in conjunction with the specific receptor affected. However, since several different neurotransmitters stimulate the CTZ, combining drugs with different mechanisms of action can often be more effective than increasing the dose of one individual drug (King and Brucker 2011). Indeed, combinations of antiemetics are often used in palliative care (NHS Scotland, n.d.). Notably, vomiting of unclear or mixed origin may respond to a phenothiazine such as prochlorperazine because, in addition to acting on dopamine and serotonin receptors in the CTZ, it also acts at the VC and vestibular area. Cyclizine and prochlorperazine are both commonly used anti-emetics in palliative care where nausea and vomiting are present in up to 70% of patients with advanced cancer (NHS Scotland, n.d.). Treating this patient population requires particular vigilance, since there may be a number of underlying reasons for and comorbidities contributing to the nausea and vomiting, and antiemetics may be inappropriate. Consideration for causes of the symptoms might include intestinal obstruction or constipation, anxiety, raised intracranial pressure (ICP), oesophageal candida, severe pain or hypercalcaemia all of which might warrant interventions other then antiemetics. Conversely, should the nausea and vomiting be identified as drug induced, then anti-emetics such as cyclyzine or prochlorperazine might be appropriate. Raised intracranial pressure stimulates vomiting centre via pressure receptors and can be problematic in patients with known or suspected brain metastases. Notable, cyclizine can be g iven to such patients, especially where corticosteroids are contraindicated (NHS Scotland, n.d.). Pharmacokinetics Cyclizine, like most antihistamines, is well absorbed from the GI tract. After oral doing the effects develop within 30 minutes, are maximal within 1-2 hours and lasts for 4-6 hours. A single oral dose of 50 mg cyclizine in healthy adult volunteers resulted in a peak plasma concentration of approximately 70 ng/mL, occurring at about two hours after drug administration. The plasma elimination half-life is approximately 20 hours.  [2]  Cyclizine is extensively metabolised in the liver via N-demethylation to the inactive metabolite norcyclizine (Figure 4), which is widely distributed throughout the tissues and has plasma half-life of approximately 20 hours. This metabolite has minor antihistaminic activity compared to parent drug. A single 50 mg dose of cyclizine when given to an adult male volunteer, results in less than 1% of the total dose administered being excreted as parent drug in the urine over a 24 h period. Thus urinary excretion of metabolite rather than parent drug is th e major route of elimination for  cyclizine. The metabolism is thought to be mediated through CYP 2D6 and therefore exhibit inter-subject variability dependent upon the CYP 2D6 genotype as demonstrated by Vella-Brincat et al. (2012) in their study of the PK of cyclizine (Appendix 1) and its major metabolite (Appendix 2) in palliative care patients receiving sub-cutaneous cyclizine. Results indicated that the metabolic ratio of parent drug to metabolite differed significantly according to CYP2D6 genetics.  [3]   Prochlorperazine is reasonably well absorbed from the GI tract and highly protein bound. It undergoes extensive metabolism both in the gastric mucosa and on first pass through the liver via the cytochrome P450 enzyme system (CYP 2D6 and CYP 3A4)  [4]  to inactive metabolites, which are subsequently excreted in the urine. Parent drug has a plasma half-life of between 4 and 8 hours, the precise half-life differing according to the mode of administration. An im injection produces its antiemetic effect in 5-10 minutes and it lasts for 3-4 hours. Onset of effects are related to the mode of administration hence the pharmacokinetic profile, thus an oral dose would have a slightly slower onset of action but would last longer compared with an im injection.  [5]  According to Finn et al (2005), although the drug has been accepted as a useful anti-emetic for over half a century, its therapeutic success has been limited by its low and variable absorption and high first-pass metabolism. H owever, the development of a new buccal formulation has improved the PK, since studies demonstrate that buccal administration of prochlorperazine produces plasma concentrations more than twice as high as an oral tablet, with less than half the variability (Finn et al., 2005)  [6]  (Figure 5). When placed in the buccal cavity between the upper lip and the gum the formulation forms a gel from which the prochlorperazine is released and absorbed. The plasma levels achieved at steady-state on a dosage regimen of one 3mg buccal tablet twice daily are similar to those observed with the standard oral dosage of one 5 mg tablet taken three times daily. The elimination half-life of prochlorperazine in this formulation is 9 hours. The safety and efficacy of this relatively new formulation has also been demonstrated by Bond  [7]  (1998) in a randomised, double-blind, double-dummy trial in patients with vestibular disorders. Side effects By virtue of their pharmacology, cyclizine and prochlorperazine are both central depressants and can cause impairment of performance (Benson, 2001). Consequently, the pharmaceutical data sheets for both drugs have warnings regarding their potential to interfere with the ability to drive or operate machinery safely due to their ability to cause drowsiness (BNF, 2012). Despite the fact that cyclizine is one of the older antihistamines it is considered less potent in this regard compared to others in its class (Broccatelli, 2010), however, there is considerable variability in response to this side effect which can range from slight drowsiness to deep sleep. For this reason in practice, when one drug is not effective or poorly tolerated then it is justifiable to give another drug or combination of drugs (Benson, 2001). This unwanted side-effect is also a feature of prochlorperazine especially in the elderly, and often diminishes with continued treatment of both drugs (emc, n.d.). Cyclizines other more common side-effects include headache and psychomotor impairment plus antimuscarinic effects, such as urinary retention, dry mouth, blurred vision, and gastrointestinal disturbances (BNF, 2012). Less common side effects are palpitations and arrhythmias, also dizziness, hypotension, muscular weakness and poor coordination (Goodman and Gilman, 1975). Prochlorperazine commonly causes CNS related side effect such as acute dystonia or dyskinesia, however these tend to be transitory (usually occur within the first 4  days of treatment) and are more common in children and young adults. Dopamine antagonists like prochlorperazine can also cause extrapyramidal effects, QT prolongation and even severe hypotension, especially in the elderly (emc, n.d.). Muscle spasms and restlessness are other reported side effects. Interactions Cyclizine exhibits pharmacological interactions with other drugs due to antagonism of its action (donepezil, galantamine, rivastigmine) or enhanced anticholinergic actions (tacrine, trimethobenzamine, triprolidine, trospium). Pharmacokinetic interactions may arise since cyclizine is an inhibitor of the hepatic CYP 2C9 isozyme system, which is involved in an NADPH-dependent electron transport pathway. This isozyme oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics and contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenytoin, tolbutamide and losartan. Pethidine and propanidid are also listed as having a potential to interact with cyclizine. Cyclizine also acts as an inhibitor of estrogen sulfotransferase, the enzyme responsible for estradiol metabolism. Prochloperazine has a plethora of interactions, both pharmacological and pharmacokinetic. The pharmacokinetic interactions are largely due to competitive metabolic interactions at the hepatic CYP 3A4 and CYP 2D6 enzymes. The CYP 3A4 isozymes are responsible for a variety of oxidation reactions e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1-hydroxylation and midazolam 4- hydroxylation, plus metabolism of structurally unrelated compounds, including steroids, fatty acids, and many other xenobiotics. Whilst the CYP 2D6 isozymes are responsible for the metabolism of many drugs and environmental chemicals, via oxidative transformation along with metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.  [9]  Consequently, the data sheet for prochlorperazine lists many drugs with interaction potential including adrenaline, amphetamine, carbamazepine, clonidine, desferrioxamine, guanethidine, levodopa, lithium, phenobarbital and propranolol. Managing Drug Therapy When managing the care of a patient, nursing staff must initially thoroughly assess the patient, then identify significant interactions between core drug knowledge (PD, PK, ADRs, interactions, contraindications) and the patients core variables (health status, age and gender, life-style and diet, environments, culture). Thereafter the nurse can plan and implement suitable interventions, which will maximise therapeutic effects whilst minimising adverse effects (Aschenbrenner and Venable, 2008). In order to achieve such objectives the nurse should ensure administration of the appropriate medication is given through a suitable route on a regular basis or as required, with ongoing patient evaluation and monitoring. Cyclizine and prochlorperazine are both considered first line treatments for nausea secondary to vertigo and motion sickness (Quigley, 2001) and are first line treatments in many hospitals in PONV (NHS, Salisbury; NHS Plymouth). A review by Matchar, et al. (2003) has suggested that oral prochloperazine may also be used as an adjunct in the treatment of nausea associated with migraine (Matchar et al, n.d.). No randomized controlled trial has been found which formally compares efficacy of cyclizine and prochlorperazine, however, two studies comparing cyclizine with perphenazine in ameliorating drug-induced emesis, have shown the former to have comparable antiemetic efficacy to this related phenothiazine drug (Dundee et al., 1975; Chestnutt and Dundee, 1986). These studies are featured in a Cochrane report (Stevenson, 2006) which investigates drugs for preventing PONV and highlights eight drugs which reduce PONV by a similar amount in this patient group, cyclizine being one. The report concluded, therefore, that the most important question to answer when treating emesis is What are the types and risks of side effects experienced by patients exposed to these antiemetics? Thus safe and effective prescribing requires the nurse to identify patient variables or comorbidities relevant to the drugs side effects, for example heart failure patients should not be prescribed cyclizine and individuals susceptible to visual disturbances should avoid prochlorperazine as per the drugs contraindications. It is noteworthy that both drugs may be prescribed in the later stages of pregnancy if considered appropriate by a doctor (Schaefer, 2007; CKS, n.d.).  [10]   The choice of antiemetic would depend upon the precise cause of the nausea in conjunction with the specific receptor affected. However, since several different neurotransmitters stimulate the CTZ, combining drugs with different mechanisms of action can often be more effective than increasing the dose of one individual drug (King and Brucker 2011). Indeed, combinations of antiemetics are often used in palliative care (NHS Scotland, n.d.). Notably, vomiting of unclear or mixed origin may respond to a phenothiazine such as prochlorperazine because, in addition to acting on dopamine and serotonin receptors in the CTZ, it also acts at the VC and vestibular area. Cyclizine and prochlorperazine are both commonly used anti-emetics in palliative care where nausea and vomiting are present in up to 70% of patients with advanced cancer (NHS Scotland, n.d.). Treating this patient population requires particular vigilance, since there may be a number of underlying reasons for and comorbidities contributing to the nausea and vomiting, and antiemetics may be inappropriate. Consideration for causes of the symptoms might include intestinal obstruction or constipation, anxiety, raised intracranial pressure (ICP), oesophageal candida, severe pain or hypercalcaemia all of which might warrant interventions other then antiemetics. Conversely, should the nausea and vomiting be identified as drug induced, then anti-emetics such as cyclyzine or prochlorperazine might be appropriate. Raised intracranial pressure stimulates vomiting centre via pressure receptors and can be problematic in patients with known or suspected brain metastases. Notable, cyclizine can be g iven to such patients, especially where corticosteroids are contraindicated (NHS Scotland, n.d.). Administration Precautions Due to its centrally acting effects, patients taking cyclizine should avoid alcohol and other depressants e.g. hypnotics or tranquillisers. Food may reduce irritation to cyclizine and since there is no interaction with food, this drug can be taken without regard to meals. The datasheet indicates it should be used with caution in hepatic disease, whilst in renal impairment there is a need for dose reduction (BNF, 2012). Cyclizine should also be used with caution in patients with severe heart failure. Other anticholinergic effects include visual disturbances, and sedation, which can make them dangerous for the elderly population or younger patients. Further, cardiovascular side effects e.g. hypotension, tachycardia, and palpitations have been reported, plus minor GI effect e.g. dry mouth and constipation. Cyclizine has a well-known abuse potential (Ruben et al. 2006). In opiate dependents receiving long-term methadone cyclizine is often taken in large doses intravenously to provide a m ore intense high. Thereafter the addict experiences depressive mood changes and a craving for cyclizine. Many individuals receiving long-term prescriptions of oral methadone have been identified as being habitual abusers of cyclizine.  [11]  Consequently, there is considerable reticence by pharmacists in prescribing the drug, and alternative treatments are generally sought. Obviously in the hospital setting there is little opportunity for such abuse, and the efficacy and cost-effectiveness of the drug would therefore take precedence over its abuse potential (Barber, 1995; Philips and Thompson, 1997). Although prochlorperazine being an antipsychotic phenothiazine drug can be employed in psychiatry, in lower doses it is usually prescribed for its anti-emetic properties. Patients taking the drug should take with a full glass of water, avoid excessive quantities of coffee or tea (containing caffeine) and also avoid alcohol. Prochlorperazine should be used with caution in patients with renal and hepatic impairment and cardiovascular disease; also in Parkinsons disease, epilepsy and in patients with a history of glaucoma. While the drug does not deliver the euphoria that is associated with many commonly abused drugs, it still has some abuse potential since it can alter mood and perception, but not to the extent of cyclizine. Moreover, dependence and tolerance can develop, which can drive the individual to continue to seek more of the drug  [12]  and result in overdose, characterised by symptoms of central nervous system depression to the point of somnolence or coma. Agitation and r estlessness may also occur in overdose. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus. Managing Drug Therapy Nausea and Vertigo: In emetic patients, antiemetics should only be prescribed when the underlying cause is known, indeed antiemetic administration may be harmful when the cause can be treated, e.g. in diabetic ketoacidosis or digoxin/antiepileptic overdose. In addition to motion sickness cyclizine can be given to patients with nausea caused by mechanical bowel obstruction and raised intracranial pressure.  [13]  Once a decision has been made that antiemetic drug treatment is appropriate, the drug and the dosage form should be chosen according to the aetiology of vomiting along with core drug knowledge and patient variables. Thus prochloperazine is useful for episodes of more severe nausea and vomiting e.g. associated with diffuse neoplastic disease, radiation sickness, and the emesis caused by drugs such as opioids, general anaesthetics, and cytotoxics. Indeed, prophylactic use may be required if severe nausea is anticipated such as following chemotherapy treatment. (Aschenbrenne r and Venable, 2008). Prochorperazine may be a suitable choice because of its dosage forms, thus rectal suppositories can be useful in patients with persistent vomiting or with severe nausea and the buccal tablet dosage form is also useful in such instances. However, during use of phenothiazines it is important to monitor severe dystonic reactions, especially in children. It is recommended as a second-line treatment for vomiting in pregnancy after promethazine.  [14]   Whereas the efficacy of cyclizine in treating nausea and vomiting has already been unequivocally proven, it is only available in tablet and injectable form. Nevertheless, cyclizine may be the choice of drug over prochlorperazine in children since in this patient population the latter can only be administered orally (BNF, 2012), and therefore requires patient compliance for success. There is no evidence that either of the two drugs is superior to the other in terms of efficacy; also despite cyclizines longer plasma half-life compared with prochlorperazine, the duration of action is similar at around 4 hours. The adverse event profiles do however differ slightly, because of the differing underlying pharmacology of these two drugs. This is an important consideration in the choice of drug, alongside special precautions which, as described earlier, must be considered in conjunction with patients co-morbidities. It is also noteworthy that educating patients and their families regarding the drug of choice is important; for example warning patients against consuming alcohol with both prochlorperazine and cyclizine and warning patients against driving or operating machinery if susceptible to drowsiness with either drug. In summary, both cyclizine and prochloperazine have similar safety, tolerability and toxicity profiles despite their differing modes of action on a cellular level. Tolerability in terms of drowsiness is a potential problem for both drugs, but is generally dependent upon the individual patients susceptibility, warranting a trial and error type approach when determining which is the optimal drug of choice. Also, due to the drugs both being substrates of CYP 2D6 their phamacokinetic profiles may exhibit inter-subject variability by virtue of the different phenotypes of this enzyme which exist in the population. This differing pharmacokinetic profile would logically translate into a varied response in terms of therapeutic effects. Likewise, their potential to interact with other drugs is inextricably linked with their metabolism, namely metabolic competition at the cytochrome P450 enzyme receptor sites. Thus both drugs have the potential to interact with a wide range of other medications . Moreover, since both drugs are extensively metabolised in the liver, with excretion of metabolites in the urine, there is a need for caution in renal and hepatic disease. Cyclizine and prochlorperazine appear to be similarly efficacious with regard to their treatment of emesis caused by motion sickness. The literature is inconclusive regarding which drug would be more superior for PONV, or vertigo, and even though it has been suggested that prochlorperazine should be chosen over cyclizine when the nausea is severe, there does not seem to be any compelling evidence for this and many hospitals tend to choose cyclizine over prochlorperazine in their antiemetic protocols/guidelines. The most compelling evidence for choosing prochlorperazine over cyclizine in the primary care setting would be the high abuse potential with cyclizine. However, in the secondary care setting this is of minimal concern. Therefore a more compelling reason for choosing prochlorperazine over cyclizine in this setting might largely hinge on the greater flexibility in formulations available for prochlorperazine. Whereas both drugs can be given orally as a tablet, when patients are vomiting this may be inappropriate. The buccal tablet or rectal suppository, which is available for prochlorperazine, and is less invasive than an injection formulation may be more acceptable to many patients in such cases. To conclude, the present essay has demonstrated that the nursing process for effectively dealing with emesis is challenging and complex. Here we have witnessed the plethora of facts which the nurse must take into account prior to prescribing the antiemetic drugs cyclizine and prochlorperazine, and that even after attempting to optimise drug selection on the basis of such facts, success cannot be guaranteed. Ongoing monitoring of patient response/progress with the possibility of altering or augmenting the chosen drug therapy is necessary to improve outcomes, ensure patients receive optimal care, and that they enjoy maximal therapeutic success with minimal side effects. References Matchar DB, Young WB, Rosenberg JH, Michael P. Pietrzak, Stephen D. Silberstein, Richard B. Lipton and Nabih M. Ramadan. Evidence-based guidelines for migraine headache in the primary care setting: Pharmacological management of acute attacks. Available at: www.aan.com/public/practiceguidelines/03.pdf/. Accessed 28/10/12. CKS: Clinical Knowledge Summaries http://www.cks.nhs.uk/nausea_vomiting_in_pregnancy/management/prescribing_information/prochlorperazine/advice_about_prochlorperazine Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 607). Benson A J, Medication for Motion S

Victimization of Women in a Male Dominated and Male Defined World :: Exploratory Essays Research Papers

The brutality and ruthless insidiousness of the male dominated scientific regime can be seen in stark silhouette when one comes to understand how even theories constructed for no purpose other than to entrench male privilege and power fall victim to the ram-rod assault of Linear Progress. For example, the belief that the entire human organism in miniature form -- the homunculus -- was contained in the spermatozoa, was predicated on the assumption that the male is normative and active -- ejaculating its will and its likeness out into a passive female world. The female, in this view, served only as a nutritive field -- a convenient cuntainer in which the male-generated miniature man could grow. In some versions of the story, the father's right testicle was thought to produce male offspring, while the left [1] testicle was thought to suffer from insufficient blood flow, resulting in defective spermatozoa, producing a substandard, or female homunculus. The fact that the scientific perspective [2] has shifted on the subject of human reproduction in no way exonerates science from its male bias. The entire scientific enterprise is at its root an expression of the universal male lust to apprehend and gain control over external reality. The masculine need to project maleness ever further out into the world hints at the motivations behind the overthrow of the homunculus as the active instrument of procreation: plausible deniability. By seeming to involve the woman as an "equal participant" and a contributor of substance to the procreative process, the universal Male Agendum (rape) can be masked behind the veil of necessary female complicity. By this diabolical shift away from unabashed male aggressiveness, toward the illusion of sexual equality, through the subterfuge of sperm-meets-egg, Western, maledominated Science has simultaneously placated women and given men a license to rape. Given the notion that women are equal participants in the programme of heterosexual intercourse, men are free to absolve themselves of full culpability. Further, by giving women a role in the generative process that is seen (presumably at least by the men who propound the sperm-meets-egg theory) to be more invested than being merely fertile soil for sowing by men, Science has preempted the deconstruction of homunculus theory and the development of feminist and wymynyst counterparts. penelope ann has suggested the beginnings of just such a theory in chapter 7 of her book Fixing Our Fathers [3]. ann has postulated the honuncula as the mostly-formed, diminutive proto-woman that exists within the so-called ovum.

Against Working Mothers

Fatima Saucedo Mr. Lewton English 101 6 December 2012 The Value of Stay-At-Home Moms Now days, many people tend to look down at stay-at-home moms rather than working mothers. This happens to many women, making it more difficult for them to choose between their children or work. For the first time in twenty-five years, the percentage of mothers returning to the workforce has fallen from fifty-nine percent in 1998 to fifty-five percent in 2000 (Adrienne Fox, Jan. 2002). This shows that women have more of a lifestyle choice rather than an economic choice.For mothers, it is a hard decision to make, but staying at home with their children is a better choice. Children need the affection and attention of their mothers. The reason I am against working mothers is because it is important to have a motherly figure during growth, as children behave better, and daycare is not the appropriate substitution for proper motherly care. Stay-at-home mothers also have the privilege of enjoying their chil dren’s â€Å"firsts†. Their first steps, their first words, and their first haircut.Experiencing these â€Å"firsts† while giving them praise and encouragement will induce children to feel secure and wanted. According to Dr. Laurence Steinberg, a professor of physiology at Temple University in Philadelphia, good parenting helps lower the chances for anxiety, depression, eating disorders, antisocial behavior, alcohol and drug use. No mother would want their children growing up with a higher chance of these disorders or behaviors. Having a mother at home brings daughter and son to mother relationships closer, not only physically but also emotionally as well.Infants who receive enough attention †¦ from a loving adult right from the start are more likely to succeed socially and emotionally (Betty Holcomb)       It is risky for infants to be away from their moms for more than twenty hours per week. Psychologists claim babies who are separated from their moth ers may tend to act out in school, cause trouble in life, or even have poor relationships as adults (Betty Holcomb). A very important advantage a mother has is she can discipline her child more consistently when being at home.The child’s values and morals can be guided. Kids are going to behave better and act out less for attention; especially if these values and morals are enforced since newborns. Not only will they behave well in school, they will have good grades. This is because parents will be able to manage their time more effectively to be able to focus on their children’s education. The children’s homework will be making sure it is completed, with a stay-at-home mom looking out for them.In some families, it is actually less expensive for one parent to stay at home than to pay for childcare. Not only the cost of childcare is saved, there is also the issue of feeding the family. If there is a stay-at-home mom, the need for quick â€Å"take-out food† is dramatically reduced. This is usually the case for working mothers, because they are either too tired or do not have enough time to cook a meal for her family. Also, mothers do not need to worry about how their child is doing in daycare.Two studies, one by the National Institute of Child Health & Development and the other by the Institute of Child Development from the University of Minnesota have both found that children who spend all day in daycare have higher levels of stress and aggression than kids who stay at home with moms. The research in the year 2010 confirmed these results. They show that it continues to negatively impact even after they’ve reached adolescence. Just like the other studies, biological psychologist Megan Gunnar and her colleagues found stress in babies.In their research, three-month old babies who received the mother’s consistent care had less cortisol stress than those who did not (The Natural Child Project). On the other side, studies cla im that children of working mothers have more chances of being successful in life. From 1975 to 1990, the work labor force for women has grown especially for those with children (Howard Hayghe 1998). Mothers like to be independent and have a feeling of satisfaction; it makes them happier, therefore better mothers. They can’t be fulfilling happy if the know someone else is enjoying them in daycare.According to the opponents, children who are in daycare starting from one month and on have a better language and cognitive ability than children at home. Due to this they will tend to have higher reading scores as well (Peters 1997). Because it is important to have a motherly figure during growth, as children behave better, and daycare is not the appropriate substitution for proper motherly care, mothers should take in mind of staying at home with their children. Children shouldn’t be forced to a routine out of their reach. Not only will children of stay-at-home moms will be comfortable, but mom will too.

Adhesion molecules in T-cell receptor

Adhesion molecules or receptor play key role in many processes involving cellular immunity that included haematopoiesis, migration, activation and finally apoptosis. They are mainly surface glycoproteins and variation among them is mainly due to different pattern of glycosylation. Adhesion molecules play a central role in T cell activation by providing initial temporary attachment of TCR and Antigen bearing MHC on APC. It was clearly demonstrated by various studies where complete inhibition of cellular immunity was observed in response to Monoclonal antibody against many of these adhesion molecules.Cytotoxic CD8 T cells mediated immunity play a key role in viral infection control. It exerts it effect by close cellular interaction with viral infected target cells. Adhesion molecules play a crucial role in driving the effector T cell towards viral infected target cell as well as to establish interaction between TCR and APC. This article briefs the function and properties of some vital adhesion molecules such as LFA-1, ICAM and VLA-4. Further, research carried out to assess the role of adhesion molecules in T-cell receptor is also summarized.Thymus derived (T) lymphocytes are important regulatory and effectors cells in immune responses. The specificity of cellular immunity is mediated by T cell receptor-CD3 complex interacting with foreign antigen represented by MHC molecule (BARBARA E. , 1988). Activation of T cells leads to functioning of T Cells where it produces various cytokines and cell lyses. In general, CD4+ T cells act as helper cells by producing different effectors molecules after interacting with antigen bearing APC cells, whereas CD8+ cell directly exert it’s effect by killing the antigen bearing APC cells.Activation and generation of effectors T cells are mediated by TcR-CD3 complex but there are several other surface molecules that play a significant role in immune response and T cell adhesion to APC. Similarly, they have significant role in cell migration, homing and recirculation. Some recent reports indicate the role of these molecules in T cell activation and differentiation. Among many are LFA-1, CD2, CD4, and CD8. Each of these molecules interact with it ligands for example LFA-1 binds to ICAM-1 while LFA-3 bind to CD2 etc. (BARBARA E. , 1988) LFA-1:The LFA-1 molecule is member of a family of three related proteins found on lymphoid and myeloid cells having common Beta subunits of MW 95000. They are non covalently associated with a unique alpha subunit. Two other members of LFA-1 families are CR3 and p150. LFA-1 molecules are widely distributed on all thymocytes, T cells, B cells, and natural killer cells. Identification of LFA-1 was done when monoclonal antibodies against it was used to inhibit cytotoxic T cell mediated killing and later on it was found to be key molecules which helps in TCR-APC interaction as adhesion molecules.Similar observation are made where anti LFA- 1 monoclonal antibody inhibits spontaneo us aggregation or homotypic adhesions between EB virus mediated activated T cells. This clearly indicates the role of LFA-1 in strengthening the intersection. Any abnormality in expression of these groups of adhesion molecules leads to recurrent bacterial and viral infection and abolished Cytotoxic T cell mediated immunity. (BARBARA E. , 1988) ICAM (Intra cellular Adhesion Molecules): Intercellular Adhesion Molecule-1 (ICAM-1, CD54) is a transmembrane glycoprotein molecule of the immunoglobulin super family.Each of the molecules is made up of 5 distinct domains and coded by gene present on chromosome 19. It is 80-114 KDa protein having 505 amino acid residues. ICAM associated with receptor of integrin family and having key role in cell signaling and adhesion. A CD8 T cell utilizes temporary interaction between ICAM-1 and LFA-1 to initiate binding of TcR and antigen MHC. This temporary interaction or binding provides sufficient time to T cell to recognize Antigen and respond against it by activation. (BARBARA E. , 1988)The T-cell lymphocyte migration is influenced by the interactions via the adhesion molecules, the T cell receptor and cytokines. (Hauzenberger D, 1995). The motility of the T cell lymphocytes is very much and critically dependent upon the avidity of the adhesive lymphocyte receptors for endothelial cells ligand and extracellular matrix componenets and the capability of the lymohocytes to undergo a motile response. Hauzenberger D et al. , 1995 discussed that the lymphocytes are rendered motile by adhesion to endothelial cells and ECM components.This migration, which is considered directed is mediated by beta-1-integrins and special T-cell lymphocytes that possess functional specialization using either alpha 4 beta 1 or alpha 5 beta 1 during chemotaxis and hapotaxis to ECM components. It is also reported that the T cell antigen receptor cannot itself trigger T lymphocyte migration to fibronectin, laminin or collagen type IV but works in hand with s ignals via alpha 4 beta 1. (Hauzenberger D, 1995) Adhesion molecules and Systemic viral Infection: Research Studies Virus induced changes in the adhesion molecules expression on T-cells were studied by Andersson et al., 1997. They studied how the antiviral effector cells migrate into the infectious foci. It was revealed by the FACS (Fluorescent associated Cell sorting) that when systemic lymphocytic choriomeningitis viral infection occurs in cells, various cell adhesion molecules including VLA-4, LFA-1, and ICAM-1 are up regulated on CD8+ cells. The lymph node homing receptor MEL-4 was down regulated during infection, but they observed only marginal changes in CD4+ cells. Further analyses showed that T cells with a changed adhesion molecule profile presented many other cell surface markers, thus indicating a state of cellular activation.The activation was of IL-2R, and included all virus-specific CTL effectors. The researchers concluded that the hypothesis that indicates that the up regulation of VLA-4 is important for effectors T cell homing to sites of inflammation. (Andersson EC, 1994). In Concanavalin induced Hepatitis, the TNF-? induced expression if Adhesion molecules are under the control of TNFR1. This study was performed by Worl et al. , in 2001. Hepatocellular death by activation of TNFR1 is mediated, apart from this TNF also in responsible for activation of cytokines and adhesion molecules.Also leads to massive induction of adhesion molecules, like ICAM-1, VCAM-1 and E-selecting in the liver. The study also revealed, that the absence of any of the TNFrs did not change the adhesion molecules expression in the livers of ConA treated mice which leads to the conclusion that the other endothelial cell-activating cytokines up-regulated adhesion molecules expression. This study discusses the critical role of adhesion molecules, such that the upregulaton of adhesion molecules during hepatitis not only contributes to organ injury but also represent defense m echanism. (Dominik Wolf, 2001) Rhinoviruses cause common colds.This form of common cold has over 100 serotypes, the major group share a single receptor. Lymphocyte function associated molecule 1 (LFA-1) mediates leukocyte adhesion to a wide variety of cell types by binding to intercellular adhesion molecule 1 (ICAM-1). Donald E. Staunton et al. , 1989 demonstrated identity between the receptor for the major group of rhinoviruses and ICAM-1. The studies revealed that a major group rhinovirus binds specifically to purified ICAM-1 and to ICAM-1 expressed on transfected COS cells and binding is blocked by three ICAM-1 monoclonal antibodies (MAb) that block ICAM-1-LFA-1 interaction.These studies also suggested that the ICAM-1 contact site(s) for LFA-1 and rhinoviruses is identical. Moreover, ICAM-1 MAb block the cytopathic effect in HeLa cells mediated by representative major but not minor group rhinoviruses. The researcher’s concluded that intercellular adhesion molecule 1 is ind uced by soluble mediators of inflammation, suggesting that the host immune response to rhinovirus may facilitate spread to uninfected cells. (Donald E. Stauntonb, p. 1989) Apart from ICAM1 and LFA-1, other categories of adhesion molecules functioning in T cell receptors include E-selectin and vascular cell adhesion molecule-1.These adhesion molecules mediate adult T-cell leukemia cell adhesion to endothelial cells. Ishakawa et al. , 1980 studies the adhesion properties of peripheral bold leukemic cells form 10 patients with adult T-cell leukemia to endothelial cells to derive the mechanism of leukemic cell infiltration. ATL cells did express LFA-1 but the expression of VLA-4 was variable. These results, together with the detection of E-selectin expression on the endothelium at ATL skin lesions, indicated that the E-selectin-mediated adhesion is the major pathway for the adherence of ATL cells to endothelial cells.Moreover, the ligand for E-selectin on ATL cells appears to differ fro m that on neutrophils. (T Ishikawa, 1993) Bibliography Andersson EC, C. J. (1994). Changes in cell adhesion molecule expression on T cells associated with systemic virus infection. Journal of Immunology , 1237-45. BARBARA E. , B. I. (1988). T cell adhesion molecules. FASEB , 2584-2590. Dominik Wolf, R. H. (2001). TNF–Induced Expression of Adhesion Molecules in the Liver Is Under the Control of TNFR1 Relevance for Concanavalin A-Induced Hepatitis.The Journal of Immunology , 1300-1307. Donald E. Stauntonb, a. V. (198). A cell adhesion molecule, ICAM-1, is the major surface receptor for rhinoviruses. Cell , 849-853. Hauzenberger D, K. J. (1995). T lymphocyte migration: the influence of interactions via adhesion molecules, the T cell receptor, and cytokines. Crit Rev Immunol. , 285-316. T Ishikawa, A. I. (1993). E-selectin and vascular cell adhesion molecule-1 mediate adult T-cell leukemia cell adhesion to endothelial cells. Blood , 1590-1598.